[1]Song D, Meng T, Xu W, et al. 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis. Bone. 2015;78:46-54. [2]Wei CM, Liu Q, Song FM, et al. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo. J Cell Physiol. 2018;233(1):476-485. [3]Zhang T, Zhao K, Han W, et al. Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo. J Cell Physiol. 2019; 234(3):2719-2729. [4]Chen Y, Wang X, Yang M, et al. miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin. Med Sci Monit. 2018;24:5292-5300.[5]Thummuri D, Naidu VGM, Chaudhari P. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling. J Mol Med (Berl). 2017;95(10): 1065-1076. [6]Wang W, Yang L, Zhang D, et al. MicroRNA-218 Negatively Regulates Osteoclastogenic Differentiation by Repressing the Nuclear Factor-κB Signaling Pathway and Targeting Tumor Necrosis Factor Receptor 1. Cell Physiol Biochem. 2018; 48(1):339-347.[7]Song F, Wei C, Zhou L, et al. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. J Cell Physiol. 2018;233(2): 1723-1735. [8]Kim HJ, Park C, Kim GY, et al. Sargassum serratifolium attenuates RANKL-induced osteoclast differentiation and oxidative stress through inhibition of NF-κB and activation of the Nrf2/HO-1 signaling pathway. Biosci Trends. 2018;12(3):257-265.[9]Sapkota M, Li L, Kim SW, et al. Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice. Food Chem Toxicol. 2018;120:418-429.[10]Choi JK, Jang YH, Lee S, et al. Chrysin attenuates atopic dermatitis by suppressing inflammation of keratinocytes. Food Chem Toxicol. 2017;110:142-150.[11]Zeinali M, Rezaee SA, Hosseinzadeh H. An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. Biomed Pharmacother. 2017; 92:998-1009.[12]Ramírez-Espinosa JJ, Saldaña-Ríos J, García-Jiménez S, et al. Chrysin Induces Antidiabetic, Antidyslipidemic and Anti-Inflammatory Effects in Athymic Nude Diabetic Mice. Molecules. 2017;23(1):E67. [13]George MY, Esmat A, Tadros MG, et al. In vivo cellular and molecular gastroprotective mechanisms of chrysin; Emphasis on oxidative stress, inflammation and angiogenesis. Eur J Pharmacol. 2018;818:486-498. [14]Mani R, Natesan V, Arumugam R. Neuroprotective effect of chrysin on hyperammonemia mediated neuroinflammatory responses and altered expression of astrocytic protein in the hippocampus. Biomed Pharmacother. 2017;88:762-769.[15]Zheng W, Tao Z, Cai L, et al. Chrysin Attenuates IL-1β-Induced Expression of Inflammatory Mediators by Suppressing NF-κB in Human Osteoarthritis Chondrocytes. Inflammation. 2017;40(4):1143-1154.[16]Jiang Y, Gong FL, Zhao GB, et al. Chrysin suppressed inflammatory responses and the inducible nitric oxide synthase pathway after spinal cord injury in rats. Int J Mol Sci. 2014;15(7):12270-12279. [17]Eldutar E, Kandemir FM, Kucukler S, et al. Restorative effects of Chrysin pretreatment on oxidant-antioxidant status, inflammatory cytokine production, and apoptotic and autophagic markers in acute paracetamol-induced hepatotoxicity in rats: An experimental and biochemical study. J Biochem Mol Toxicol. 2017;31(11):e21960.[18]Chen Y, Dou C, Yi J, et al. Inhibitory effect of vanillin on RANKL-induced osteoclast formation and function through activating mitochondrial-dependent apoptosis signaling pathway. Life Sci. 2018;208:305-314. [19]Tang R, Yi J, Yang J, et al. Interleukin-37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction. J Cell Physiol. 2019;234(5):7645-7658. [20]Dharmapatni AASSK, Algate K, Coleman R, et al. Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro. Inflammation. 2017;40(5):1566-1575. [21]Crockett JC, Rogers MJ, Coxon FP, et al. Bone remodelling at a glance. J Cell Sci. 2011;124(Pt 7):991-998.[22]Suda T, Nakamura I, Jimi E, et al. Regulation of osteoclast function. J Bone Miner Res. 1997;12(6):869-879.[23]Muruganandan S, Dranse HJ, Rourke JL, et al. Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis. Stem Cells. 2013;31(10):2172-2182. [24]Wu X, Chim SM, Kuek V, et al. HtrA1 is upregulated during RANKL-induced osteoclastogenesis, and negatively regulates osteoblast differentiation and BMP2-induced Smad1/5/8, ERK and p38 phosphorylation. FEBS Lett. 2014;588(1):143-150.[25]Kim JY, Min JY, Baek JM, et al. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Bone. 2015;79:242-251. [26]Jeong E, Choi HK, Park JH, et al. STAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex. Cell Death Differ. 2018;25(8):1364-1374. [27]Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol Cells. 2017;40(10):706-713.[28]Obaid R, Wani SE, Azfer A, et al. Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget's Disease. Cell Rep. 2015;13(6):1096-1102. [29]Krauss JL, Zeng R, Hickman-Brecks CL,et al. NLRP12 provides a critical checkpoint for osteoclast differentiation. Proc Natl Acad Sci U S A. 2015;112(33):10455-10460.[30]Gu Z, Wang H, Xia J, et al. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015;75(11):2211-2221.[31]Jie Z, Shen S, Zhao X, et al. Activating β-catenin/Pax6 axis negatively regulates osteoclastogenesis by selectively inhibiting phosphorylation of p38/MAPK. FASEB J. 2018. doi: 10.1096/fj.201801977R.[32]Zhang HQ, Wang YJ, Yang GT, et al. Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo. Pharmacology. 2019;103(1-2):101-109. [33]Wang W, Huang M, Hui Y, et al. Cryptotanshinone inhibits RANKL-induced osteoclastogenesis by regulating ERK and NF-κB signaling pathways. J Cell Biochem. 2018. doi: 10.1002/jcb.28008. [34]Rehman MU, Ali N, Rashid S, et al. Alleviation of hepatic injury by chrysin in cisplatin administered rats: probable role of oxidative and inflammatory markers. Pharmacol Rep. 2014;66(6):1050-1059. [35]Kats A, Gerasimcik N, Näreoja T, et al. Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs. J Cell Mol Med. 2019;23(2):1152-1163. [36]Kim HJ, Yoon HJ, Kim SY, et al. A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-κB signaling and blocks cytoskeletal organization and survival in mature osteoclasts. Mol Cells. 2014;37(8):598-604. [37]Kaneko K, Miyamoto Y, Tsukuura R, et al. 8-Nitro-cGMP is a promoter of osteoclast differentiation induced by RANKL. Nitric Oxide. 2018;72:46-51. [38]Chai L, Zhou K, Wang S, et al. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro. Cell Physiol Biochem. 2018;48(5): 2123-2133. |